Blaming the rapid increases in syphilis cases on PrEP is an oversimplification of a complex problem.
Articles on PrEP
Displaying 41 - 60 of 63 articles
World AIDS Day is Dec. 1. With many advances in preventing and treating the disease, the disease has fallen from top of mind for many. An epidemiologist explains why that could be dangerous.
Researchers from the BC Centre for Excellence in HIV/AIDS share the latest research on HIV prevention, treatment and stigma.
Modern factors are seeing a revival of the STI that was once consigned to history.
Doctors in South Africa performed a liver transplant from an HIV-positive donor to a HIV-negative recipient. Major ethical questions came into play.
Recently PrEP, an effective drug against HIV, was in the news with some concerns that gay men are no longer using condoms. But is the issue about condoms or control?
An increase in condomless sex in PrEP users is predictable as preventing HIV is the key motivator for condom use among gay and bisexual men.
Sharing data about users’ HIV statuses is bad enough. But why collect it in the first place?
The HIV prevention drug Truvada (PrEP) will be listed on the Pharmaceutical Benefits Scheme from this Sunday, moving Australia closer to achieving its goal of ending new HIV transmissions by 2020.
HIV self-testing is a potential strategy to overcome access to testing. However, there are emerging concerns on the lack of counselling, possible user error and accuracy of the kits.
PrEP may be giving some homosexual and heterosexual users a false sense of security.
South Africa’s data rollout of its pre-exposure prophylaxis shows that there is a relatively slow, but increasing, uptake. However, more needs to be done to target young women.
Stigma stops people from getting tested for HIV, and staying on their treatment. Unless it’s addressed, the AIDS epidemic will persist.
Trials have shown that rates of HIV infection are reduced if people not infected with HIV take anti-retrovirals - known as pre-exposure prophylaxis (PrEP). But adherence to a daily dose is a problem.
Ignoring those at ‘high risk’ of HIV in order to sustain the idea of the ‘good’ gay man will only perpetuate the virus.
A judge has found that NHS England cannot reasonably refuse to fund anti-HIV drugs for gay men. This is a major step forward.
The focus of the 2016 International AIDS Conference has on access to necessary antiretrovirals, equity and making sure no-one is left behind. But there is a funding gap that needs to be addressed.
Thanks to treatment advances, people with HIV can and do live long and full lives. And that has led to a challenge that doctors and patients may not have imagined 35 years ago: the aging HIV patient.
Just how much disclosure is it reasonable to expect from a sex partner, particularly if that relationship isn’t a serious and committed one?
Used properly and consistently, condoms are the most effective, affordable, and low-tech way to prevent HIV. But unfortunately, condoms are not an easy option for everyone – particularly women.
Top contributors
-
Professor of medicine and deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town
-
Associate Professor of Health Law, Policy and Management, Boston University
-
Associate Professor, Public Health Ethics, School of Population Health, UNSW
-
Assistant Professor of Social, Behavioral and Population Sciences, Tulane University
-
Assistant Professor of Public Health, University of Iowa
-
Post-doctoral researcher, KEMRI-Wellcome Trust Research Program, Kenya Medical Research Institute
-
Lecturer in Public Health and Primary Care, Bangor University
-
Professor, School of Health Sciences, University of Northern British Columbia; University of Victoria
-
Associate professor in Health Psychology, University of Copenhagen
-
Associate Professor and Director: Research at the Wits Reproductive Health and HIV Institute I, University of the Witwatersrand
-
Research Director at Donald Gordon Medical Centre, University of the Witwatersrand
-
Assistant Lecturer, University of Warwick
-
Momentum Postdoctoral Fellow, BC Centre for Excellence in HIV/AIDS, University of British Columbia
-
Professor of Infectious Diseases, Monash University
-
PhD candidate, Ghent University